脂蛋白a与中青年冠心病的研究进展  

Study on the Correlation between Lipoprotein a and Coronary Heart Disease in Young- and Middle-Aged People

作　　者：郭明燕 刘东 

机构地区：[1]西安医学院研究生工作部,陕西 西安

出　　处：《临床医学进展》2024年第5期2054-2062,共9页Advances in Clinical Medicine

摘　　要：近年来,尽管我国医疗水平得到高速发展,在冠状动脉粥样硬化的预防和治疗方面取得显著进展,冠心病的死亡率呈现降低趋势。然而中青年的冠心病死亡率并未得到明显实质性改善。作为CAD独立危险因素的Lp(a),不同于其他血脂,因其水平不能通过传统的生活方式干预和他汀类药物治疗来改变,因此被认为是比LDL更危险的胆固醇。目前能够远期且显著使Lp(a)水平保持较低水准的治疗方案相对缺乏,因此将Lp(a)作为新的治疗靶点,以此降低心血管事件风险具有重要临床意义及研究价值。In recent years, despite the rapid development of China’s medical level, remarkable progress has been made in the prevention and treatment of coronary atherosclerosis, and the mortality rate of coronary heart disease has shown a decreasing trend. However, coronary heart disease mortality in young- and middle-aged people has not been significantly improved. Lp(a), as an independent risk factor for CAD, differs from other lipids in which its levels cannot be altered by traditional lifestyle interventions and statin therapy, and is therefore considered a more dangerous cholesterol than LDL. At present, there is a relative lack of long-term treatment options that can significantly keep Lp(a) level low, so it is of great clinical significance and research value to use Lp(a) as a new therapeutic target to reduce the risk of cardiovascular events.

关 键 词：中青年冠心病 脂蛋白A 治疗 

分 类 号：R54[医药卫生—心血管疾病]